USFDA raises concern over drug production process at Cadila

Tags: News
The US Food and Drug Administration (FDA) has expressed concerns over the manufacturing process of at least one product at drugmaker Cadila Healthcare Ltd's Moraiya facility, two sources with direct knowledge of the matter said.

The FDA has not expressed concerns over the entire facility, said the sources. The US agency communicated its concern to Cadila in a Form 483, a letter in which the agency typically outlines violations of standard manufacturing practices.

Once the Form 483 is sent, the company has 15 days to respond before the FDA takes any further action.

The FDA inspected the Moraiya plant, based in Gujarat, in the second week of July, one of the sources said.

The sources declined to be named as the information is not public yet. A Cadila spokeswoman declined to comment.

Cadila's shares dropped as much as 10.5% on Thursday and were trading down 5.3% to Rs 1,106.50 at 1:01 pm., while the broader Nifty was down 0.22%.


  • Cyrus Mistry eased out as Tata shows its heft in Bombay House

    It is a classic board room brawl, only this time, it took place in the dignified and rarified air of Bombay House, home to the venerable Tata Sons.


Stay informed on our latest news!


Ananda Majumdar

Between mobocracy and the nation

Maharashtra Chief Minister Devendra Fadnavis’ well publicised act of peacemaking ...

Rajgopal Nidamboor

The physics of mindful awareness

Philosopher Aristotle emphasised the fact that “thinking always involves thinking ...

Shona Adhikari

Owais Husain searches for a lost homeland

The seventh edition of the Mumbai Public Art Festival (PAF) ...